Frovatriptan

Frovatriptan
Clinical data
Trade names Frova
AHFS/Drugs.com Monograph
MedlinePlus a604013
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code N02CC07 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 20–30%
Metabolism Hepatic
Biological half-life 26 hours
Excretion Renal
Identifiers
Synonyms 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
(6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
CAS Number 158930-17-7 N
PubChem (CID) 77992
IUPHAR/BPS 7191
DrugBank DB00998 YesY
ChemSpider 70378 YesY
UNII H82Q2D5WA7 YesY
KEGG D07997 N
ChEMBL CHEMBL1279 YesY
Chemical and physical data
Formula C14H17N3O
Molar mass 243.304 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]

Pharmacology

Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

Mechanism of action

Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.

Adverse effects

Serious but rare cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Contraindications

Frovatriptan should not be given to patients with:

US licensing

Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006.[2]

References

  1. "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
  2. "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.
This article is issued from Wikipedia - version of the 9/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.